Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPACARD: Dapagliflozin Cardiac Effects in T2D
NCT03387683Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Feb 2018; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03387683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387683.